A meeting of the executive committee of the Board of Trustees was held on July 31, 2024, via Zoom.

Trustees Chair Ramanan Raghavendran presented a resolution to approve the transfer of assets. The Gene Therapy Program (GTP) at Penn Medicine, which is led by James Wilson, the Rose H. Weiss Orphan Disease Center Director’s Professor, has grown rapidly over the past ten years during a time of volatility of biotechnology funding, largely supported by industry-sponsored research funds. The Perelman School of Medicine (PSOM), the Penn Center for Innovation (PCI), and Dr. Wilson have been exploring ways to transition the functions and operations of GTP from Penn Medicine into externally managed entities. This transition will further advance clinical research, while fostering continued gene therapy product development that is better managed by industry. A third-party services company has shown interest in securing the service center functions and a third-party R&D company has shown interest in securing the R&D Product Functions. The resolution was approved.

Interim President J. Larry Jameson presented a resolution to appoint Stephen J. MacCarthy as Interim Vice President for University Communications, effective August 1, 2024. Mr. MacCarthy had served in that role for 12 years and has returned to it while a search is conducted for a new Vice President for University Communications.